| Michael Deininger's publications on PubMed |
Selected Publications
 | Ponatinib in refractory Philadelphia chromosome-positive leukemias. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127. |
| Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Agarwal A, Fleischman AG, Petersen CL, Mackenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW. Blood. 2012 Sep 27;120(13):2658-68. Epub 2012 Aug 13. |
| Pushing the limits of targeted therapy in chronic myeloid leukemia. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317. Review. PMID: 22825216 |
| Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW. Blood. 2011 Dec 8;118(24):6392-8. Epub 2011 Aug 22. |
| Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW. Leukemia. 2012 May;26(5):1140-3. doi: 10.1038/leu.2011.325. Epub 2011 Nov 18. |
| Curing CML with imatinib—a dream come true? Deininger, M. Nat. Rev. Clin. Oncol. 8, 127–128 (2011); published online 1 February 2011; doi:10.1038/nrclinonc.2011.17 |
| A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, Harrington CA, Deininger MW. Blood. 2010 Jan 14;115(2):315-25. Epub 2009 Oct 16. |
| BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. Blood. 2010 Oct 28;116(17):3278-85. Epub 2010 Jun 2. |
| CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. Blood. 2010 Jun 24;115(25):5232-40. Epub 2010 Apr 12. |
